Rat PK for the DYT1 lead compound

The National Institutes of Health, Office of the Director, Office of Acquisitions, is soliciting proposals under solicitation number 75N98026Q00987 for research and development services related to rat pharmacokinetics for the DYT1 lead compound. This is a competitive combined synopsis and solicitation issued under FAR Subpart 12.6 for commercial items, utilizing full and open competition without a separate written solicitation. The contract will be awarded on a firm-fixed-price basis to the offeror providing the best value to the government, with no set-aside designated and the requirement remaining unrestricted. The North American Industry Classification System code is 541715, with a small business size standard of 1,000 employees, and the solicitation is conducted under the streamlined procedures authorized by FAR 12.603, not expected to exceed the simplified acquisition threshold. Proposals must be submitted by the deadline of August 24, 2026, and all terms and conditions are governed by the Federal Acquisition Circular effective August 7, 2026. The work is to be performed in support of the NIH in Bethesda, Maryland, with primary point of contact being John Johnston, reachable via email at jaddua.johnston@nih.gov. This acquisition is not tied to any specific location beyond the agency’s office in Bethesda and is intended to procure commercial services in the field of physical, engineering, and life sciences research, excluding nanotechnology and biotechnology. All interested parties must respond through the provided SAM.gov link and adhere to the submission requirements outlined in the solicitation document.